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The development of Alternative Testing Strategies (ATS) for hazard assessment of new and emerging 
materials is high on the agenda of scientists, funders and regulators. The relatively large number of 
nanomaterials on the market and under development means that an increasing emphasis will be placed on 
the use of reliable, predictive ATS when assessing their safety. We have provided recommendations as to 
how ATS development for assessment of nanomaterial hazard may be accelerated. Pre-defined search terms 
were used to identify the quantity and distribution of peer-reviewed publications for nanomaterial hazard 
assessment following inhalation, ingestion or dermal absorption. A summary of knowledge gaps relating to 
nanomaterial hazard is provided to identify future research priorities and areas in which a rich data set might 
exist to allow ATS identification. Consultation with stakeholders (e.g. academia, industry, regulators) was 
critical to ensure that current expert opinion was reflected. The gap analysis revealed an abundance of 
studies which assessed the local and systemic impacts of inhaled particles. Development of ATS for 
assessment of the dermal toxicity of chemicals is already relatively advanced, and these models should be 
applied to nanomaterials as relatively few studies have assessed the dermal toxicity of nanomaterials, to 
date. Limited studies have investigated the local and systemic impacts of ingested nanomaterials. If the 
recommendations for research prioritisation proposed are adopted it is envisioned that a comprehensive 
battery of ATS can be developed to support the risk assessment process for nanomaterials. Some alternative 
models are available for immediate implementation, whilst others require more developmental work to 
become widely adopted. Case studies are included which can be used to inform the selection of alternative 
models and endpoints when assessing the pathogenicity of fibres and mode of action of nanomaterial 
toxicity. 





The development of Alternative Testing Strategies (ATS) for hazard assessment of new and emerging 
materials has been high on the agenda of many scientists, funders and regulators for a number of years, 
largely due to ethical concerns about using animals for toxicity testing. Growing acceptance and 
implementation of the 3Rs principles (replacement, reduction, and refinement of animal use) within the field 
of toxicology has led to regulators becoming increasingly receptive to the use of ATS to inform the risk 
assessment process.  For nanotoxicology, the need to develop ATS has become increasingly urgent due to 
the large number of nanomaterials on the market and under development for a wide range of applications.  
Such diversity of use leads to the potential for human and environmental exposure via a variety of routes, 
for which the associated risks need to be understood in order to allow nanotechnology to develop in a safe, 
responsible and sustainable manner.   
To date, assessment of nanomaterial hazard has encompassed evaluation of their local and systemic toxicity 
using a combination of in vivo and in vitro models. Over recent years the application of in silico models (e.g. 
quantitative structure activity relationships (QSAR)) to predict nanomaterial hazard has also been explored, 
however such tools are in the very early stages of development [1, 2]. A variety of different nanomaterials of 
varied physicochemical properties have been tested using traditional in vivo and in vitro methods; with silver 
(Ag), metal oxides (e.g. titanium dioxide (TiO2)), and carbon nanotubes (CNTs) amongst the most extensively 
investigated due to their high levels of use and production, and concerns regarding their safety. This has 
allowed relationships between nanomaterial physicochemical properties and toxicity to be explored. 
However, the ability to assess the potential risks of this diverse array of nanomaterials using conventional 
hazard tests is limited by time, budget and ethical considerations regarding the use of animal testing.  This is 
compounded further by the desire to understand how the hazard/risk of each nanomaterial is modified along 
the value chain (from design to successful use in products) and throughout the life cycle (from pristine 
nanomaterial to disposed or fragmented/aged product). Thus, increased use of reliable, predictive ATS for 
the hazard assessment of nanomaterials is essential. Furthermore, where possible the development of 
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(automated) high throughput (HTP) systems is desirable to enable the testing of a range of nanomaterials 
and concentrations in fewer experiments. 
There are many types of ATS, including simple in vitro systems with single cell types, in vitro co-cultures, 
complex 3D in vitro models which mimic tissue architecture (e.g. EpiDerm (skin), EpiAirway (lung)), cell-free 
assays (e.g. enzyme assays), prokaryotic bacteria (e.g. Ames Test), invertebrates (e.g. Drosophila), 
vertebrates (e.g. zebrafish) and those that incorporate in silico modeling.  For each model there are also a 
range of endpoints that can be assessed. Endpoints that have been widely reported to be associated with 
nanomaterial hazard can be investigated using ATS to screen toxicity but to also obtain a better 
understanding of the mode of action of nanomaterial toxicity, for example, inflammation, and oxidative 
stress, and the downstream consequences of these processes (e.g. genotoxicity). In addition model specific 
endpoints such as Drosophilia reproduction, zebrafish reproduction and development and systems biology 
approaches (e.g. genomics and proteomics) can be used to further explore the hazard potential of 
nanomaterials. Using ATS it is often possible to evaluate multiple parameters of interest in one experiment, 
maximising the amount of information that can be obtained from one study.  If used alone each test system 
may have limited value, however, the breadth of ATS available provides the opportunity to assess several 
endpoints simultaneously and use batteries of tests (multiple models approach) which together can provide 
a rich diversity of information.  However, assembly of this battery of models and interpretation of the data 
generated by the different ATS requires an understanding of the limitations of each model, their validation 
by comparison to animal or human study results (e.g. via in vitro in vivo extrapolation; IVIVE), and the use of 
relevant standards to allow comparability between data sets [3]. 
There is an expectation that development of ATS along these lines will substantially increase the quantity of 
hazard information on nanomaterials and their modes of action leading to (1) more effective and rapid 
screening of nanomaterials; (2) the development of in silico quantitative structure-activity relationship 
(QSAR) models  reducing risk to human health; (3) advancement of 
Adverse Outcome Pathway models and (4) development of a tiered testing strategy for assessment of hazard 
with a significant reduction, though perhaps not complete elimination in the short term of in vivo exposure 
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and hazard testing to decrease reliance on animal models when demonstrating safety for regulatory 
purposes.  
The following manuscript outlines recommendations for model and endpoint selection and development, 
and research prioritisation to promote ATS development, which if implemented could focus and speed up 
efforts to enhance the use of ATS in the risk assessment of nanomaterials. Importantly, the approach 
described is also likely to be more widely applicable to a diverse range of materials and chemicals. 
2.0 RECOMMENDATIONS FOR PRIORITISING ATS DEVELOPMENT 
The breadth of ATS available means that not all models can be developed simultaneously and to the same 
extent. Furthermore, not all ATS will be equally applicable or useful for nanomaterial hazard identification, 
therefore a need exists to prioritise ATS development.  There are several ways in which prioritisation could 
be considered, which were discussed in the context of human health and environmental risk assessment by 
the expert Society for Risk Analysis (SRA) workshop held in September 2014 in Washington DC in cooperation 
with the OECD Working Party on Manufactured Nanomaterials (see Shatkin et al, this volume).  For example, 
a systematic analysis of the current published literature allows identification of gaps in knowledge as well as 
areas in which there is a wealth of knowledge to draw upon. The literature search should not be restricted 
to nanomaterials, but include other chemicals to identify what lessons can be learnt from the development 
of existing ATS, and then applied to nanomaterial hazard assessment. It could be argued that it is a priority 
to fill the data gaps with regards to nanomaterial hazard, but development and validation of an ATS to 
represent a hazard assessment for which the hazard is not well understood and is difficult. In contrast, areas 
which are more data rich provide an opportunity to make decisions for ATS prioritisation on a strong evidence 
base. The development of ATS is more advanced in some areas than others. For example, due to EU 
regulatory bans on the use of animal testing for cosmetic safety assessment, ATS model development for  
investigation of the dermal toxicity of substances is relatively well advanced. In addition, zebrafish are a well 
established, valuable model when investigating the developmental and reproductive toxicity of substances 
[4]. ATS for nanomaterials should encourage wider application of such models for the assessment of hazard 
in relation to human (and environmental) health.   
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The following strategy to support the use of ATS in the hazard assessment of nanomaterials was discussed: 
Step 1.  Identify sources of information for the nanomaterial of interest across a variety of models (in vivo, in 
vitro, in silico) via a literature search. Material such as published literature, OECD dataset (including 14 
nanomaterials tested via a wide array of methods and laboratories), industrial datasets (e.g. REACH dossiers, 
EPA submissions) etc should be used in order to identify where there is sufficient quantity of data, consistency 
in study design and measured outcomes and therefore confidence in the hazard information available for a 
particular type of nanomaterial.  In other words, can we identify the low hanging fruit that are ripe for 
development into the ATS? 
Step 2.  Divide the data and information available into in vivo and in vitro data and within the in vitro data, 
list the in vitro tests used to assess different endpoints within an ATS, and identify which models reflect or 
predict the in vivo response.  This approach will allow identification of a short list of endpoints within an ATS 
that are worthy of further development.  It will also be essential to identify scenarios where there is no 
correlation between in vitro and in vivo studies i.e. where ATS may not be appropriate. 
Prediction of an in vivo result by an in vitro assay means one or both of the following: (1) that the results of 
an in vitro assay for several different nanomaterial variants matches the relative order of toxic responses 
observed for those same nanomaterial variants in an in vivo model endpoint; and/or (2) that the intervals of 
the toxic response observed for those nanomaterials matches the intervals of the toxic response observed in 
an in vivo model. Searches should account for the fact that certain individual in vitro assays may not have 
predictive power on their own, but may serve to improve predictions of in vivo responses in combination 
with results across multiple in vitro assays. It should also be noted that in vitro assays have the additional 
benefit that they are useful to probe mechanisms of toxicity that can help to explain in vivo observations. 
This means that it might be useful to broaden this approach to identify additional in vitro endpoints that add 
further detail to understanding the effects of nanomaterial treatments. 
Step 3.  An assessment of data quality needs to be incorporated into the literature/information sources used 
to provide the information on which the ATS shortlist is based.  This needs to include certainty around 
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materials tested (i.e. adequate physicochemical characterisation of nanomaterial properties) and certainty 
around the protocol utilised including consistency with established recommendations or norms and in the 
data obtained.  Reference to relevant human data should be considered where available. 
Step 4.  Interrogate the usefulness of the short-listed ATS further by assessment of their suitability for a range 
of nanomaterials.  For example some nanomaterials may interfere in particular assays [5] to provide false 
positive or negative results.  This interference may arise due to the surface properties of nanomaterials 
including catalytic activities [6] and also adsorptive properties [7] [8] such as indicator dyes [9] .  They may 
therefore be used in the separation of selected analytes from complex matrices [10], to transport 
macromolecules and also for in vivo imaging [11] [12]. Nanomaterials may also have optical properties [13] 
as well as 
[14]. It is therefore of no surprise that such surface properties may be operational when chromophores, 
fluorophores and luminophores are utilised in assay systems to assess a great number of cellular functional 
disturbances that may be arising from exposure to nanomaterials. As such, discrepancies may therefore arise 
between these assays depending on the extent of the effect of these surface properties on the 
chromophores, fluorophores or the luminophores used. Nanomaterials themselves may therefore interfere 
with these assay systems [15] [16], thus producing inaccurate results. 
In addition a critical analysis of the potential to develop each ATS into either a High Throughput Screening 
(HTS) or a High Content Screening (HCS) approach is needed.  When testing the developing ATS, relevant 
concentration ranges for each nanomaterial need to be identified, based on real-life exposure information, 
when available.  Within the group of ATS taken forward for this interrogation, there will need to be a selection 
of tools to evaluate the biokinetics of nanomaterials in order to identify potential for uptake, targets for 
accumulation, toxicity and also clearance due to their biopersistence.   
Within the design of each ATS, consideration will need to reflect the likely exposure scenarios (e.g. 
concentration, route) for each nanomaterial. For example, nanomaterials relevant for exposure via inhalation 
could be pre-coated in lung lining fluid before introduction into the in vitro system to better replicate real-
life exposures and mimic the transit of nanomaterials in the body [17]. 
8 
 
The development process also needs to include consideration of suitable controls (positive, negative and 
vehicle), plus controls that are relevant to certain types of nanomaterials (e.g. fibres for high aspect ratio 
nanomaterials, relevant metal salt solutions for nanomaterials that are prone to dissolution). The preparation 
of nanomaterials for hazard testing also needs to be carefully considered; there are currently a number of 
different approaches that can be used to disperse nanomaterials (e.g. sonication (probe or bath), stirring, 
and  inclusion of solvents, proteins or lipids in dispersion medium), and no consensus as to which approach 
is most appropriate and relevant to real-life exposure conditions.  
Once this process is complete a short list of prioritised ATS can then be tested with nanomaterials for which 
human and animal hazard information is available, in order to test the limitations of each ATS in relation to 
their power of predictability of the hazard of the tested nanomaterial.  The battery of ATS can then be 
compiled and interrogated further in order to standardise the protocol.  At this point, for ATS which overlap 
in terms of the information they can provide that is suitable for risk assessment, a decision can be made over 
whether the list could be streamlined further. However, it is often useful to have more than one way to 
measure the same effect, especially due to the potential for nanomaterials to interfere in some assay types 
implemented within a particular ATS. 
It is unlikely that this approach will identify ATS that are relevant for all routes of exposure, target locations 
and toxicological endpoints relevant to risk assessment.  However, once this battery of ATS is developed this 
will then allow gaps to be identified in order to focus future ATS development. It is also likely that 
nanomaterials will be transformed along their life cycle (from pristine nanomaterial to disposed or 
fragmented/aged/transformed product) and that this should be taken into consideration when performing 
hazard assessments using ATS. 
3.0 THE CURRENT STATUS OF NANOTOXICOLOGY  IDENTIFYING THE LOW HANGING FRUIT 
In 2012, the European Project ITS-NANO (http://www.nano.hw.ac.uk/research-projects/itsnano.html) 
generated a gap analysis of the human hazard literature relating to nanotoxicology.  The gap analysis included 
a systematic search of PubMed (up to December 2011) with pre-defined search terms in order to identify the 
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quantity and distribution of peer-reviewed publications that are relevant for the hazard assessment of 
nanomaterials.  These results were converted into heat map tables. A heat map is a graphical representation 
of information where each value within a matrix is represented by a colour. In this instance three colours 
were used, each representing a range of data within defined limits. The heat maps were initially used to 
generate a gap analysis of research priorities to be addressed, but for the purposes of the SRA workshop, 
they provided an opportunity to identify areas in which a rich data set might exist to allow ATS identification 
for development prioritisation.   
This list of identified research priorities was then shared with a wide range of stakeholders (e.g. academia, 
industry, regulators, NGOs, policy makers) to ensure that they reflected current expert opinion.  This was 
essential as the simple systematic literature search did not include a check of the research quality, only the 
content, and could not take into account funded research that was recently completed (but not yet 
published) and research that was still in progress.  The gap analysis was then used to generate research 
prioritisation recommendations, through consultation with these stakeholders, leading to the development 
of an intelligent testing strategy (ITS) for nanomaterials [18]. The full project report 
(http://nano.hw.ac.uk/research-projects/itsnano.html) and the publication in Particle and Fibre Toxicology 
[18] are provided for information.  Chapter 3 of the full ITS-NANO report provides the gaps relevant to hazard 
assessment and suggests strategies to address each gap. 
Prior to the SRA workshop, the ITS-NANO gap analysis tables were updated (May 2014) in order to identify 
the current status of research across different nanotoxicology relevant disciplines, and to analyse areas in 
which research activity has been most productive over the last 2 years. The workshop in Washington also 
provided an opportunity to liaise with stakeholders to update this list of research priorities and to provide an 
expert assessment of the relevance of these priorities, as well as a discussion of how these research gaps 
might be addressed. 
The heat maps were generated from the number of peer reviewed publications identified using the NCBI 
publications database, PubMed. In order to tailor the searches, a range of specific keywords were identified 
which represent each area of nanotoxicology interest in relation to hazard assessment for human health, and 
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was focused on three main routes of exposure; respiratory, ingestion and dermal (Table I). In addition, the 
searches considered the mechanism of nanomaterial toxicity, the biodistribution of nanomaterials and 
effects induced at secondary target sites (systemic toxicity), the longevity of the response (acute vs chronic) 
and the physicochemical properties of nanomaterial that confer toxicity.  Both in vivo and in vitro studies 
were identified. The publication databases were interrogated using combinations of keywords to form 
detailed and highly specific search terms. The list of publications identified during each search was examined 
to identify any duplications, irrelevant publications, or missing relevant publications. During the update (May 
2014), the publications were also checked to ensure they had not been included in the previous search 
conducted during the ITS-NANO project (2012-2014), e.g. 
as then used to construct  updated 
 
[TABLE I] 
3.1 FINDINGS FROM THE GAP ANALYSIS 
Studies focusing on assessment of nanomaterial hazard following the pulmonary route of exposure are most 
abundant (Tables II and III), when compared to either ingestion (Tables IV and V) or the dermal exposure 
route (Tables VI and VII).  A subset of studies investigated biokinetics following pulmonary exposure, which 
are also relatively abundant compared to ingestion and dermal exposure studies. 
3.1.1 Pulmonary Studies  
Pulmonary studies identified during the gap analysis include both local effects in the lung (Table II) as well as 
systemic effects (Table III), but with relatively more concentrating on systemic effects.  In terms of 
understanding the mode of action of nanomaterial toxicity, studies relating to inflammation dominate the 
pulmonary studies that identify a local effect in the lungs or in lung cells.  In comparison to inflammation, 
oxidative stress and cytotoxicity studies, investigations of fibrosis, genotoxicity and carcinogenicity are 
relatively scarce.  Note that these data are a combination of both in vivo animal models as well as in vitro cell 
culture models. In fact, a range of models were used; for in vivo testing rodent  (rats and mice) studies are 
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the most prevalent with administration via intratracheal instillation was most common, with fewer studies 
administering nanomaterials via inhalation. Such studies typically investigate inflammatory and oxidative 
stress driven pulmonary responses (e.g. via assessment of inflammatory cell infiltration, cytokine production, 
antioxidant depletion and histopathological examination). The majority of studies assessed acute effects, 
following a single administration of nanomaterials. For in vitro studies, a plethora of models have been used 
including; macrophage cell lines (e.g. J774, THP-1), bronchial or alveolar cell lines (e.g. A549, BEAS-2B), 
primary monocytes/macrophages (derived from the rat lung, or human blood), and co-culture systems (e.g. 
3D cell cultures encompassing epithelial cells, macrophages and dendritic cells).  Endpoints relating to 
cytotoxicity, cytokine production, cellular uptake of nanomaterials, oxidative stress (encompassing ROS 
production or antioxidant depletion) and genotoxicity were most prevalent in in vitro studies. 
[TABLES II and III] 
Similar to the observations for local effects, pulmonary studies considering the modes of action for systemic 
or distal effects are dominated by inflammation followed by oxidative stress with the biodistribution of 
nanomaterials following pulmonary exposure rather extensively investigated.  In comparison, longer term 
effects such as fibrosis and carcinogenicity are less abundant for the systemic effects following pulmonary 
exposure.   
[TABLES IV and V] 
3.1.2 Ingestion Studies  
To date there are very few studies published that have focused on ingestion as a route of exposure for either 
local or distal impacts of nanomaterials (Tables IV and V).  As a consequence there are few studies that 
identify the mode of action, biokinetics or the relationship between biological impact and nanomaterial 
physicochemical characteristics following ingestion. In vitro models were most prevalent and the models 
most commonly used to assess the implications of nanomaterial ingestion on the intestinal epithelium 
included Caco-2 single cell cultures (using undifferentiated or differentiated cells), with more limited studies 
using co-cultures (e.g. intestinal epithelial and immune cells; M cell model, mucus model) which more closely 
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mimics the gastrointestinal tract (GIT) epithelium in vivo. Studies typically assessed cellular responses related 
to inflammation, oxidative stress and genotoxicity. 
3.1.3 Dermal Studies  
For dermal studies, again there are relatively few published studies. Of those that have been published, the 
majority have looked at the relationship between particle size and either local cytotoxicity, inflammation or 
oxidative stress. The penetration of limited types of nanomaterials (such as quantum dots) through skin and 
potential for particle translocation has also been considered using in vitro models. Several models have been 
used including simple in vitro cell line mono-cultures (e.g. keratinocytes, fibroblasts), more sophisticated in 
vitro models which replicate skin tissue cell architecture (e.g. EpiDerm), and ex vivo tissue models (pig and 
human). Far fewer in vivo studies have been carried out, the majority of which tend to focus on rodent 
models.  
[TABLES VI and VII] 
A systematic analysis of the peer reviewed literature, as conducted here, provides an overview of the major 
areas of research activity.  Conversely, this provides an opportunity to identify areas where information is 
lacking and hence establish research needs for the future.  This information will be useful to help researchers 
and funders prioritise hazard studies in the future. Furthermore, it enables identification of commonly used 
ATS models (that have been tested for a range of nanomaterials), and where possible, comparison to in vivo 
findings. 
4.0 CASE STUDIES 
Selection of relevant and sensitive alternative models and endpoints to assess nanomaterial hazard is 
essential for appropriate interpretation of data. Existing particle and nanotoxicology research can be used to 
justify and guide model and endpoint selection and to identify the limitations of alternative models.  
4.1  Case Study 1: High Aspect Ratio Nanomaterials (HARN) & the fibre pathogenicity paradigm 
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Identifying the relationship between nanomaterial physicochemical properties and their toxicity is a critical 
component of hazard studies. This information can be used for a variety of purposes, for example it is 
required to support the design of appropriate legislation to manage the risks posed by nanomaterials and to 
encourage  generations of nanomaterials. High aspect ratio 
nanomaterials (such as carbon nanotubes (CNTs)) have a structural resemblance to asbestos fibres, causing 
concern that these materials may induce similar adverse health outcomes to asbestos in the lung (e.g. 
pathogenicity paradigm . More specifically, it is established that long (>5µm), thin 
(<100nm), biopersistent fibres are likely to be more pathogenic than shorter (<5µm), more 
agglomerated/entangled fibres (e.g. [19, 20]). This derives from the ability of long, thin biopersistent asbestos 
fibres to be deposited in the alveolar region of the lung following inhalation, where they interact with alveolar 
macrophages and mesothelial cells. Long fibres (>5µm) cannot be effectively ingested by macrophages and 
induce frustrated phagocytosis, stimulating a persistent inflammatory and oxidative response leading to 
tumour development (for reviews please refer to [19, 21]. The applicability of this paradigm to HARN (e.g. 
CNTs, silver or nickel nanowires) has been tested using in vivo and in vitro models. In vivo studies have 
typically exposed mice to CNTs, silver nanowires or nickel nanowires via intraperitoneal [22], pharyngeal 
aspiration  [23, 24] or intrapleural injection [25-27]  and assessed inflammation (e.g. differential cell counts, 
cytokine production, histopathological analysis, granuloma formation), oxidative stress and macrophage 
uptake of fibres (using microscopy) as indicators of toxicity. Such studies have provided data to support the 
applicability of the fibre pathogenicity paradigm to HARN. In vitro experiments using macrophages (primary, 
human and animal derived cells or cell lines) further support that fibre length is critical to HARN toxicity and 
that cytotoxicity, pro-inflammatory cytokine production, cellular uptake and reactive oxygen species 
production are appropriate, and sensitive markers of the biological response [23, 28, 29].  
Thus, based on existing knowledge of fibre toxicity it is possible to recommend the design of a tiered testing 
strategy which promotes the use of ATS for assessment of HARN hazard. In the first instance, assessment of 
the physicochemical properties of HARN should be prioritised within the hazard assessment, which can be 
achieved via the use of microscopy (e.g. scanning electron microscopy (SEM), transmission electron 
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microscopy (TEM), atomic force microscopy (AFM), light microscopy) to measure fibre length and diameter. 
If HARN morphology is long (> 5µm) and straight then this indicates that these fibres may be pathogenic.  It 
is also established that iron or nickel contamination can contribute to CNT toxicity [30] and so the purity of 
samples should also be confirmed via elemental analysis when characterising HARN physicochemical 
properties. Thus, characterisation of nanomaterial physicochemical properties is a key, early component of 
hazard studies for fibre-like nanomaterials and can be used to predict their pathogenicity. In vitro studies 
should then be used to assess the response of macrophages to HARN. Macrophage/monocyte cell lines (e.g. 
J774, RAW 264.7, THP-1) can be used, followed by limited studies using primary human macrophage cells to 
validate the response exhibited by cell lines, if deemed appropriate (and subject to ethical approval). 
Endpoints assessed should include i) cellular uptake of HARN by macrophages using microscopy (e.g. light 
microscopy, TEM, SEM), ii) production of pro-inflammatory cytokines e.g. tumour necrosis factor alpha 
(TNF , interleukin (IL)-1  and iii) respiratory burst (production of reactive oxygen species (ROS)). It is advised 
 In order 
to confirm the findings from in vitro experiments it may be appropriate (e.g. to fulfil regulatory requirements) 
to perform limited, focused in vivo (rodent) studies in order to assess fibrosis and mesothelial cell response. 
4.2 Case study 2: Mechanism of action of nanomaterial toxicity 
A better understanding of the mode of action of nanomaterial toxicity will help support the development of 
a battery of sensitive, evidence based tests that can be used to screen nanomaterial toxicity using alternative 
models. Existing information on the mechanism of toxicity of particles and nanomaterials can be used to 
inform the selection of ATS when testing the toxicity of a nanomaterial of unknown hazard. Prior to the 
emergence of nanotechnology and hence nanosafety research, most particle toxicology was related to 
respiratory exposures, including occupational dusts (e.g. asbestos [31], silica [32] and coalmine dust [33]) and 
air pollution particles (PM10, e.g. [34]).  The study of occupational and environmental particles identified 
oxidative stress and inflammation as key processes in controlling the pathological responses to these 
particles in humans.  For example, both asbestos and PM10 have been shown to induce glutathione depletion 
and ROS production [35, 36] which is indicative of oxidative stress, stimulate activation of the oxidative stress 
responsive transcription factor nuclear factor kappa B [37, 38], activate Ca2+ signalling, and increase 
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expression and production of pro-inflammatory cytokines such as interleukin-8 and  [39, 40].  The 
discipline of particle toxicology is well established, and with due regard for the physicochemical and 
toxicological differences that nano-sized materials have compared to their bulk counterparts, provides an 
additional source of information on which to base ATS identification and prioritisation.  We suggest that this 
historical information on particle toxicology can be exploited to design hazard studies for nanomaterials, 
using in vitro and in vivo models.  
 
As described above, regardless of the target site under investigation in in vitro and in vivo hazard studies for 
nanomaterials, assessment of pro-inflammatory and oxidant responses are common. We suggest that hazard 
studies continue to assess such responses, but also expand the endpoints investigated to enable a better 
understanding of the cellular and molecular events underlying nanomaterial toxicity. In the first instance, in 
vitro experiments should be conducted, using cell lines that are appropriate to the target site of interest, to 
probe the cell and molecular events underlying nanomaterial toxicity. Such studies should assess cytotoxicity 
(e.g. alamar blue, WST-1, neutral red, lactate dehydrogenase (LDH) assays) over a range of nanomaterial 
concentrations to identify sub-lethal concentrations of nanomaterials to test using more in depth 
mechanistic studies. When investigating the mechanism of toxicity we suggest that the information obtained 
from each individual study is maximised. For example, the cells themselves can be used to assess a number 
of different responses (e.g. cytotoxicity, cellular uptake of nanomaterials, oxidative stress (ROS production, 
antioxidant depletion), activation of transcription factors, changes in protein levels/activity, changes in gene 
expression, intracellular Ca2+ concentration), whilst the cell supernatant (from the same experiment) can be 
used to measure indicators of sub-lethal and lethal effects (e.g. cytokine production, release of lactate 
dehydrogenase respectively). Where possible, highthroughput systems should be used, ideally using 
automated approaches. Genomics and proteomics analysis may also provide guidance as to which endpoints 
to consider when screening nanomaterial toxicity. Focused studies using primary cells may be conducted to 
validate the findings obtained from cell lines.  In vitro studies will inform the design (e.g. selection of 





The main observations from our gap analysis are that studies investigating the consequences of pulmonary 
exposure dominate the literature in comparison to ingestion and dermal routes of exposure.  For these 
studies, inflammation and oxidative stress account for the majority of studies investigating the mode of 
action.  These publications include those using inflammation (e.g. neutrophil infiltration, cytokine 
production) as a biomarker of hazard rather than an investigation of the mode of action. The pulmonary 
studies include a relatively large number of biokinetic studies as well as the investigation of both local and 
systemic effects.  This suggests that researchers in the field recognise a need to investigate particle 
translocation and its consequences.  This information can also be used to better design in vitro studies, 
whereby knowledge of nanomaterial biodistribution could be used to select relevant target sites to 
investigate and can be used to inform the preparation of nanomaterials for in vitro hazard studies. More 
specifically studies could suspend nanomaterials in lung lining fluid (LLF) then serum to mimic the transit of 
nanomaterials from the lung to other sites in the body via the blood (e.g. liver). The literature relevant to 
pulmonary exposure, including cytotoxicity, inflammation and oxidative stress therefore provides a suitable 
starting point for identification of suitable ATS to be developed and validated. 
In addition, a better understanding of the mode of action of nanomaterial toxicity will lead to the 
identification of evidence based approaches to screen nanomaterial toxicity in ATS, and also inform the 
potential consequences of human exposure to nanomaterials. This suggests a need for future research 
activities to investigate the mode of action, and if possible link to the physicochemical characteristics of 
nanomaterials. As discussed above, this information can be used to feedback into, and inform and prioritise 
ATS and endpoint selection for nanomaterial hazard assessment.  
Inflammation, oxidative stress and cytotoxicity studies in general relate to acute pulmonary responses in the 
lung and lung cells, whereas in comparison, the studies requiring longer term, and/or repeated pulmonary 
exposures (fibrosis, genotoxicity and carcinogenicity) are relatively scarce.  This is likely to be driven by the 
financial, ethical and practical difficulties of conducting longer term studies.  Short term inhalation studies (5 
day exposures followed by a 28 day investigation) [41-43] have been developed as an alternative to longer 
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term (e.g. 90 day) studies, in order to minimise the suffering to animals and reduce the cost.  However, there 
is clearly a need to conduct more long term inhalation/pulmonary studies for nanomaterial hazard 
assessment. To facilitate their utility, ATS also need to be adaptable and facilitate the testing of toxicity of 
nanomaterials in the long term or following repeated exposures (e.g. [44]).  
Research of the consequences of nanomaterial ingestion or dermal exposure has lagged behind those of 
pulmonary studies. Studies on the impact of nanomaterials on the skin do not generally investigate 
toxicity/hazard specifically, the majority are investigating the potential for nanomaterial penetration, rather 
than hazard. This leads to a larger number of publications investigating biokinetics and the potential for 
uptake into dermal cells and translocation of topically applied nanomaterials to other organs of the body. 
However, many of the dermal studies investigating penetration have often identified the skin as an effective 
barrier to nanomaterials (e.g. [45]), possibly reducing the urgency of funders and scientists to investigate this 
route of exposure.  However, skin is exposed purposefully (e.g. sunscreens and cosmetics) and accidentally 
(e.g. occupational exposure) to nanomaterials, and not all skin types are equally effective, with integrity being 
affected by disease status, sunburn and age.  More research would therefore be useful with compromised 
skin models [46] and repeat dosing to simulate sunscreen and nanomedicine use.  Investigation of the skin 
irritancy and sensitisation potential of nanomaterials has also been neglected. The OECD have offered 
guidance on the strategy to assess skin sensitisation and irritation using ATS which should be followed, 
although the applicability of such test guidelines to nanomaterials requires investigation. 
Relatively few studies have evaluated the impact of nanomaterials on the GIT. As observed for the lung and 
skin, existing studies have focused primarily on assessment of cytotoxicity, inflammatory and oxidative 
endpoints using in vitro models (intestinal epithelial cells). There is some evidence that some nanomaterials 
are able to cross the intestinal barrier and accumulate in secondary target sites [47], however the applicability 
of these findings to more diverse forms of nanomaterials needs to be assessed. In vitro models have been 
used primarily to assess the consequences of nanomaterial ingestion for the GIT. However the physiological 
relevance of the models used needs to be considered and the complex cell architecture, and the low oxygen 
content of the GIT should be better represented in in vitro hazard studies in the future. However, the use of 
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such complex models is often more time consuming and expensive than more simplistic single cell cultures. 
Furthermore, the need to disperse nanomaterials in physiological media that considers the transit of 
nanomaterials through the GIT within in vitro studies should be evaluated, to improve physiological 
relevance. For example acidic conditions of the stomach can modify the physicochemical properties of 
nanomaterials and therefore their behaviour in the GIT. There has been a lack of in vivo studies which have 
assessed the implications of nanomaterial ingestion for the GIT. However, further research is required in this 
area as recent studies have observed a disturbance in the diversity and abundance of GIT microflora following 
nanomaterials ingestion which may lead to adverse health outcomes.  
Existing statistical modelling studies connecting nanomaterial characteristics to toxic outcomes, which the 
development of ATS should accelerate, have either focused exclusively on the results of in vitro cytotoxicity 
studies (e.g. [48-50]) or in vivo pulmonary inflammation studies [51]. The success of these analyses suggests 
that the approach advocated here for the development of ATS is feasible, however in the short-term, the 
utility to nanomaterial risk assessment of an approach that investigates only on one portion of the in vitro  
in vivo divide is limited. The recommendations outlined here should enable a connection to be developed 
between these two model approaches, while pointing to the more informative nanotoxicology assays in both 
realms, and clarifying which nanomaterial characterisation measures are essential.  
6.0 CONCLUSION 
Finally, the SRA workshop participants generated recommendations to prioritise ATS development for 
assessment of nanomaterial hazard.  In the short term the ATS developed will reflect models and endpoints 
for which the field of nanotoxicology is already relatively confident (e.g. selection of models and endpoints 
to assess pulmonary toxicity), and so it will simply move these frequently used and tested methods towards 
standardised (validated) protocols to be used more directly for risk assessment. However, it is not possible 
to generate a battery of ATS that can cover all forms of nanomaterials, potential routes of exposure, targets 
for toxicity or types of toxicological consequence. As demonstrated in the case studies, some ATS are suitable 
for immediate use within the hazard assessment of nanomaterials, whereas other models require further 
development to identify whether they are suitable for more widespread use. Therefore, further ATS 
19 
 
development, along with in vivo testing and/or human epidemiology will be required to generate a 
comprehensive battery of ATS able to fully support the risk assessment process.  
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Table I. Gap analysis: keys words, used in combination to form detailed search-terms used for PubMed 
database searches. 
Nano-relevance 
(for all searches) 
(ultrafine OR nanoparticle OR nanoparticulate OR nanomaterial OR nanotube 




(inhalation OR instillation OR aspiration OR intraperitoneal OR air liquid 
interface) 
Gastrointestinal Ingestion 
Dermal (dermal OR skin) 
Physicochemical properties 
Size Size 
Surface area (SA) surface area 
Charge surface charge 
Aspect ratio aspect ratio 
Solubility Solubility 




(cytotox* OR necrosis OR apoptosis OR cell death OR tryptan blue Or lactate 
dehydrogenase OR LDH OR MTT OR Sulforhodamine OR WST) 
Inflammation 
(inflam* OR macrophage OR cytokine OR neutrophil OR PMN OR lymphocyte 




(oxidative stress OR oxidant OR reactive oxygen species OR ROS OR active 
oxygen species OR radical OR anti oxidant OR glutathione OR lipid peroxidation 
OR 8-oxoDG OR OHdG) 
Fibrosis (fibro* OR ECM OR TGF beta OR Collagen OR hydroxyproline) 
Genotoxicity 
(genotox* OR mutation OR comet assay OR micronucleus OR OHDG OR 
chromosome OR genetic toxicity) 
Carcinogenic 
(carcinogenic OR carcinogen OR tumour OR mutagenic OR mutagenicity OR 
carcinogenicity) 
Biokinetics 
(biokinetics OR toxicokinetics OR biodistribution OR translocation OR uptake 
OR internalisation OR endocytosis) 
Systemic targets 
Lung 
(lung OR inhalation OR instillation OR pulmonary OR aerosol OR aspiration OR 
intraperitoneal) 
Liver (liver OR hepat* OR reticuloendothelial OR kupffer OR bile OR cholestasis) 
Spleen/immune (spleen OR reticuloendothelial OR immune) 
Central nervous 
system (CNS) 
(nervous system OR brain OR nerve OR neural OR blood brain barrier OR 
olfactory OR neuro) 
Gastrointestinal (GI) 
Tract 
(gut OR ingestion OR stomach OR intestin* OR peyers OR bowel OR food) 
Kidney (kidney OR renal OR filtration OR glomerulous) 
Cardiovascular (CV) 
(heart OR endothelium OR blood OR platelets OR clotting OR thrombosis OR 
nitric oxide OR atherosclerosis OR plaque OR stroke OR infarction) 
Reproduction/ 
development 
(sperm OR oocyte OR fetus OR foetus OR reproductive OR developmental OR 
fertility) 
Pleura (retention) (pleura* OR mesothelium OR stomata) 




Table II.  Publications related to pulmonary exposure, physicochemical properties and biological impact: 
Total published as of May 2014 
 Biological impact 
PC properties Cytotoxicity Inflammation 
Oxidative 
stress 
Fibrosis Genotoxicity Carcinogenicity 
Size 85 206 69 21 9 23 
SA 14 49 19 2 4 7 
Charge 1 7 2 1 0 1 
Aspect ratio 3 8 0 1 0 2 
Solubility 9 7 6 1 4 3 
Crystallinity 13 24 11 0 2 0 
Composition 6 14 8 0 3 2 
 
Key: n = number of publications 
n < 15 
 





Table III. Publications related to pulmonary exposure, systemic effects following pulmonary exposure: 
Total published as of May 2014 
 Biological impact 
Target Biokinetics Cytotox Inflammation 
Ox. 
stress 
Fibrosis Genotox Carcinogenicity 
Lung 170 157 445 158 36 31 29 
Liver 51 11 19 17 1 6 2 
Spleen/immune 42 7 42 6 1 0 2 
CNS 35 8 25 21 1 2 2 
GI Tract 3 1 2 0 0 0 0 
Kidney 27 11 13 3 1 0 1 
CV 42 26 80 46 1 1 1 
Repro/dev 3 0 8 5 1 5 2 
Pleura (retention) 3 0 12 3 2 1 0 
 
Table IV.  Publications related to oral exposure, physicochemical properties and biological impact: Total 
published as of May 2014 
 Biological impact 
PC properties Cytotoxicity Inflammation 
Oxidative 
stress 
Fibrosis Genotoxicity Carcinogenicity 
Size 4 3 3 0 2 4 
SA 2 0 1 0 0 0 
Charge 0 0 0 0 0 0 
Aspect ratio 0 1 0 0 1 0 
Solubility 0 0 0 0 0 0 
Crystallinity 1 0 2 0 0 1 
Composition 1 1 1 0 0 1 
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Table V. Publications related to oral exposure, systemic effects following oral exposure: Total published as 
of May 2014 
 Biological impact 
Target Biokinetics Cytotox Inflammation 
Ox. 
stress 
Fibrosis Genotox Carcinogenicity 
Lung 5 3 2 1 0 0 2 
Liver 5 3 0 2 0 1 0 
Spleen/immune 1 0 2 1 0 1 1 
CNS 3 1 0 1 0 0 0 
GI Tract 18 11 5 6 1 4 6 
Kidney 3 3 0 0 0 1 0 
CV 6 2 1 2 1 1 1 
Repro/dev 0 4 0 2 0 1 0 
Pleura (retention) 1 2 0 1 0 0 0 
 
Table VI.  Publications related to dermal exposure, physicochemical properties and biological impact: Total 
as of May 2014 
 Biological impact 
PC properties Cytotoxicity Inflammation 
Oxidative 
stress 
Fibrosis Genotoxicity Carcinogenicity 
Size 36 19 21 6 10 3 
SA 3 2 1 0 0 1 
Charge 4 2 1 0 1 1 
Aspect ratio 1 0 1 0 1 0 
Solubility 2 1 1 0 1 1 
Crystallinity 5 3 4 1 1 0 




Table VII. Publications related to dermal exposure, systemic effects following dermal exposure: Total as of 
May 2014 
 Biological impact 
Target Biokinetics Cytotox Inflammation 
Ox. 
stress 
Fibrosis Genotox Carcinogenicity 
Lung 3 2 3 0 0 2 2 
Liver 7 2 3 2 2 2 1 
Spleen/immune 5 1 6 0 0 0 1 
CNS 4 2 0 2 2 1 0 
GI Tract 3 0 1 0 0 1 0 
Kidney 4 0 1 0 1 0 0 
CV 7 1 3 0 0 0 0 
Repro/dev 1 0 0 0 0 0 0 
Pleura (retention) 1 0 0 0 0 0 0 
 
 
